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Abstract 
Hyponatremia is a common electrolyte derangement in the setting of the intensive care unit. Life‑threatening neu‑
rological complications may arise not only in case of a severe (<120 mmol/L) and acute fall of plasma sodium levels, 
but may also stem from overly rapid correction of hyponatremia. Additionally, even mild hyponatremia carries a poor 
short‑term and long‑term prognosis across a wide range of conditions. Its multifaceted and intricate physiopathology 
may seem deterring at first glance, yet a careful multi‑step diagnostic approach may easily unravel the underlying 
mechanisms and enable physicians to adopt the adequate measures at the patient’s bedside. Unless hyponatremia 
is associated with obvious extracellular fluid volume increase such as in heart failure or cirrhosis, hypertonic saline 
therapy is the cornerstone of the therapeutic of profound or severely symptomatic hyponatremia. When overcor‑
rection of hyponatremia occurs, recent data indicate that re‑lowering of plasma sodium levels through the infusion 
of hypotonic fluids and the cautious use of desmopressin acetate represent a reasonable strategy. New therapeutic 
options have recently emerged, foremost among these being vaptans, but their use in the setting of the intensive 
care unit remains to be clarified.
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Background
Hyponatremia is the single most frequent electrolyte dis-
turbance encountered in the intensive care unit (ICU) 
affecting as many as 24.5  % of the patients, depend-
ing on its biochemical definition [1]. Indeed, critically 
ill patients often cumulate multiple prerequisite factors 
rendering them susceptible to hyponatremia, namely 
impaired free water excretion, frequent administration of 
hypotonic fluids, and multiple morbid and drug-related 
conditions known to predispose to hyponatremia [1–3].
Symptoms associated with hyponatremia encompass 
a broad spectrum of clinical presentations ranging from 
subtle cognitive deficiencies to life-threatening neuro-
logical impairment including status epilepticus and brain 
herniation.
Furthermore, hyponatremia is known to be closely 
associated with an altered prognosis among critically 
ill patients [4–6] and this holds true even in the face of 
mildly decreased levels of sodium plasma (PNa) levels.
Not only does hyponatremia represent a serious threat 
for patients but its management also represents a great 
challenge for clinicians. In the setting of profound, symp-
tomatic and acute hyponatremia, failure to timely cor-
rect, at least in part, hyponatremia places the patient at 
risk of hyponatremic encephalopathy, seizure and brain 
herniation whereas an overly rapid increase in plasma 
sodium concentration renders patient vulnerable to the 
much dreaded osmotic demyelination syndrome (OD) 
[7].
Herein, in this first part of a review on hyponatremia in 
the setting of the intensive care unit, we examine the key 
issues related to physiological principles, clinical mani-
festations of hyponatremia as well as the physiopathology 
of OD and its clinical aspects.
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Basic principles of sodium and water equilibrium
Although an extensive description of the physiopathology 
is beyond the scope of this study, a few principles ought 
to be kept in mind when examining the pathophysiol-
ogy of hyponatremia. They can be summed up as follows: 
(1) the vast majority of cell membranes are permeable to 
water, with the notable exception of neurons. (2) In con-
trast, ions and other solutes (except urea in most clinical 
conditions) may not freely cross cell membranes, they 
are termed effective osmolytes. (3) Therefore these effec-
tive osmolytes contribute to tonicity which is the osmotic 
gradient relative to the differential concentrations of 
osmolytes across cell membranes. (4) Water moves across 
cell membranes in order to achieve an osmotic equilib-
rium, in other words the osmotic gradient across cell 
membranes dictates the distribution of water between 
the intracellular and extracellular compartments. (5) At 
the point of equilibrium, intracellular and extracellular 
osmolality are identical. (6) Given that the total osmolar 
content of the intracellular compartment is twice as high 
as that of the extracellular compartment, the total body 
water is divided accordingly. (7) Electrolytes and water 
disturbances, whether they concern the intra- or extracel-
lular compartment, first occur via alterations of the extra-
cellular compartment, which is located at the interface 
with the external environment. (8) Under physiological 
conditions, plasma osmolality is strictly regulated so that 
changes in sodium balance translate into variations of the 
extracellular volume. (9) Conversely, intracellular osmo-
larity is preponderantly determined by water balance. (10) 
At variance with extracellular compartment where the 
predominant electrolytes are sodium and chloride, the 
intracellular compartment is composed chiefly of organic 
osmolytes. (11) Hence, the intracellular osmotic content 
is slow to adapt when the sodium and water content of 
the extracellular compartment is disturbed. (12) This also 
implies that extracellular hypo- or hyperosmolality will 
result in increased or decreased cell volume, respectively. 
(13) Water and sodium balances are regulated through 
differential pathways. (14) Arginine vasopressin (AVP) 
is the key determinant of water balance and allows for a 
tight control of plasma osmolality, as any large and sus-
tained variations of osmolality would otherwise compro-
mise the cell volume, integrity and functions [8, 9]. (15) 
Plasma sodium is the preponderant cation in the extracel-
lular compartment whereas potassium predominates in 
the intracellular compartment. (16) As predicted by Edel-
man, plasma sodium concentration is a function not only 
of total exchangeable sodium and total body water but 





where PNa stands for plasma sodium concentration, Nae 
total exchangeable sodium and Ke total exchangeable 
potassium. (17) Consequently, a noticeable decrease in 
the total potassium body content will induce a decrease in 
plasma sodium concentration.
Osmoregulation and key regulators of the sodium 
and water equilibrium
Osmosensors: collecting the osmotic stimuli
Whenever plasma osmolality undergoes variations 
exceeding 1–3  % of its pre-set value (~290  mOsm/
kg H20), homeostatic mechanisms are unleashed in an 
endeavor to restore its normal value [11]. The nature 
and intimate cell structure of these “osmosensors” 
remain elusive. Nevertheless, it is believed that these 
osmotic receptors act as neurons and are thus capable 
of converting plasma osmolality variations into elec-
tric signals [12]. Central osmoreceptors are the key 
players in this dual process of osmolality sensing and 
transduction. They are found in different areas of the 
central nervous system (CNS) including the organum 
vasculosum laminae terminalis (OVLT), which serves 
as the primary central osmoreceptors, but their pres-
ence has also been suggested in the supraoptic nucleus 
(SON) and the subfornical organ [13]. The signal 
stemming from these peripheral osmoreceptors is then 
routed to the CNS through the vagus nerve. These 
structures transduce an osmotic stimulus into a nerv-
ous signal via transient receptor potential vanilloid 1 
and 4 (TRPV1 and 4) proteins which constitute a large 
cation channel family. Cellular shrinkage caused by 
hyperosmolality triggers the opening of these channels 
which in turn causes the depolarization of these neu-
rons [14]. A fine illustration of the pivotal involvement 
of TRPV channels in the osmoregulatory process is 
provided by animal models with impaired expression 
of TRPV1 in which case they display chronic hyperos-
molarity despite having free access to fluids [15]. Simi-
larly, trpv4−/− mice display defective osmoregulation 
when subjected to an osmotic challenge [16]. Aside 
from these central receptors, fluctuation in plasma 
osmolality is also captured by osmotic sensors dis-
seminated along the digestive tract and its blood ves-
sels both in humans and other mammals [17, 18]. For a 
detailed review in a central mechanisms of osmosensa-
tion and systemic osmoregulation, please refer to [12], 
figure 3.
Once the CNS has collected and integrated the data 
stemming from peripheral and central osmotic receptors, 
it elicits compensatory responses through multiple effec-
tors, namely: AVP release, thirst and salt appetite regula-
tion, and natriuresis.
Page 3 of 27Rafat et al. Ann. Intensive Care  (2015) 5:39 
Arginine vasopressin: regulating water excretion
Arginine vasopressin: general considerations
Arginine vasopressin, a 9-amino-acid cyclic peptide, is 
synthesized in the SON and paraventricular nuclei (PVN) 
magnocellular neurons, yet it is transported by axons and 
both stored and released by the neurohypophysis. The 
two key determinants of AVP synthesis and secretion are 
osmotic stimuli and effective blood volume variations. 
Indeed, the pattern of AVP release is well articulated 
within the network of osmoreceptors. In fact, the mag-
nocellular neurons receive afferences from the neurons 
located in the OVLT and SON [19, 20] as well as periph-
eral osmoreceptors [17]. Taurine, one of the organic 
osmolyte excreted by glial cells as part of the “regulatory 
volume decrease” also acts as a neurohumoral media-
tor by dampening the release of AVP in the setting of 
hypoosmolality [21]. Finally, magnocellular neurons 
themselves may also display osmoreceptive properties in 
a similar fashion to neurons of the OVLT and the SON 
[22].
The mechanism whereby AVP regulates water balance 
is by increasing the renal collecting ducts’ permeability to 
water. Indeed, once it has been released in the systemic 
circulation, AVP binds to the V2 receptor, a 7-transmem-
brane domain protein coupled to G-proteins which is 
located on the basolateral surface of the collecting ducts. 
The ensuing intratubular cascade of events involves 
AMPc/PKA dependent pathways and culminates in the 
expression of aquaporin-2 (AQP2) water channels in the 
luminal surface of the collecting ducts, whereas they lay 
dormant niched in intratubular vesicles in the absence 
of AVP stimulation. AQP2 thus serves as the regulated 
water entry route inside the tubule, as opposed to the exit 
route which depends upon constitutively expressed water 
channels (AQP3 and AQP4) found in the basolateral 
membrane of the tubules. However, the passive flux of 
water from the lumen of the tubule back to the systemic 
circulation is conditioned by the existence of an osmotic 
gradient between the tubular lumen (low) and the kid-
ney’s interstitium (high), itself rendered possible by the 
corticopapillary gradient. [23]. AVP plays a vital part in 
sustaining this osmotic drive by enhancing the number of 
sodium channels (ENac), thus promoting sodium reab-
sorption in the cortical and outer medulla [24, 25]. For 
a comprehensive review and schematic representations 
of the interactions between AVP and the collecting duct, 
please refer to [26], figures 4 and 5.
Arginine vasopressin: osmotic regulation
Increase in effective plasma osmolality (which equates 
hypernatremia in most instances) stimulates AVP release 
in a linear fashion. On the contrary, decrease of effective 
osmolality (hypoosmotic hyponatremia) decreases AVP 
release [27]. As a result from AVP variation, values of 
urine osmolality may span from 50 to 1200  mOsm/kg 
of water in young and healthy subjects with an average 
value of 600 mOsm/kg of water [28]. Variations of plasma 
osmolality as small as 1–2  % induce noticeable varia-
tions of plasma AVP values which in turn promote sig-
nificant variations of urine osmolality [29]. AVP is thus 
instrumental in the fine-tuning of water-free excretion in 
response to changes in plasma osmolality. Furthermore, 
the short half-life of AVP allows for a swift adaptation of 
the osmoregulatory system on a minute-to-minute basis 
[27].
The role of hemodynamic and cardiovascular stimuli 
on arginine vasopressin release
Equally as important as osmotic stimuli, effective arte-
rial blood volume is a potent regulator of AVP release. 
In fact, arterial underfilling even prevails over osmotic 
stimuli, in case of competing and antagonist effects on 
AVP secretion. Whenever arterial blood underfilling is 
encountered, in such opposite circumstances as “true 
hypovolemia” or so called “effective hypovolemia” a 
clinical picture commonly found in decompensated cir-
rhosis and congestive heart failure, AVP release is elic-
ited, even if PNa is decreased. In these clinical settings, 
patients with “effective hypovolemia” typically exhibit 
both neurohormonal patterns of arterial underfilling and 
an increased extracellular fluid volume status (ECFV) 
with interstitial edema and expanded total plasma and 
blood volume, in contrast with patients with “true hypov-
olemia”. The corresponding clinical picture is one of non- 
maximally diluted urine and an excessive water load will 
inevitably give rise to hyponatremia.
This is thanks to carotid, aortic and atrial baroreceptors 
which sense arterial unloading and relay the stimulus to 
the PVN and the SON via neural afferents alongside the 
vagus and glossopharyngeal nerves and the nucleus of the 
solitary tract. The result encompasses a wide selection of 
cardiovascular and hemodynamic effects mediated by the 
V1a receptor [30]. The vasopressor effect is indeed one of 
the best known actions of AVP and is a prominent com-
ponent of compensatory mechanisms in case of severe 
hypovolemia (true or effective). It is rendered possible 
by the presence of V1a receptors in smooth muscle cells, 
over a broad range of vascular beds. In addition, AVP 
enhances the sensitivity of the baroreflex arch, perhaps 
though V1 receptors located in the area postrema [31] 
and may reinforce the sympathetic activity [32]. Other 
relevant actions of AVP on blood pressure control are 
indirectly mediated by the stimulation of mineralocorti-
coid [33] and glucocorticoid functions [30].
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Regulation of thirst
Plasma osmolality is a powerful determinant of thirst 
as a rise of as few as 5–10  mOsm/kg is sufficient to 
induce thirst [34]. Neurofunctional imaging has pro-
vided insights on the areas of the CNS which appear to 
be associated with the consciousness of thirst, the ante-
rior cingulate and the insula being the foremost of these 
[35]. The subfornical organ and the OVLT, in addition 
to their osmoreceptive attribute, also integrate inputs 
deriving from peripheral receptors and systemic factors 
[36]. Among the latter, angiotensin II should be noted 
for being a remarkable dipsogenic stimulus [37] and 
is elevated in conditions of both “true” and “effective 
hypovolemia”.
Salt appetite
Compared to thirst which manifests itself within 1–2  h 
following an increase of plasma osmolality, increased salt 
appetite is a delayed behavioral change which may take 
days to emerge. Furthermore, hyponatremia per se is not 
the prime trigger for increased salt intake [38]. In fact, 
rather than osmotic stimuli, hypovolemia (either true or 
effective), which is detected by peripheral baroreceptors 
[39, 40] and augmented levels of aldosterone and angio-
tensin II [41], are more likely to play leading roles in pro-
moting enhanced salt appetite. Putative or documented 
brain structures implicated in salt appetite are numer-
ous and their full description would stretch beyond the 
framework of this review. Extensive reviews on the topic 
can be found in [42, 43].
Control of natriuresis
Handling of sodium excretion by the kidney is complex, 
involves a great number of humoral and neurohumoral 
mediators dedicated at defending the effective arterial 
blood volume. More specifically, in patients who display 
“effective hypovolemia”, either caused by systemic arte-
rial vasodilation or a decrease in cardiac output, arte-
rial underfilling represents the unifying determinant 
which triggers this cascade of neurohormonal responses. 
Alongside the secretion of AVP, the plasma renin-angi-
otensinogen-aldosterone system (RAAS) is activated. 
Renal arterial vasoconstriction ensues causing a fall in the 
glomerular filtration rate. This phenomenon, combined 
with the direct effect of enhanced angiotensin II activity, 
promotes proximal tubular sodium reabsorption. In addi-
tion, arterial underfilling also unleashes the activation of 
the sympathetic nervous system (SNS) which acts as yet 
another major player. Not only is the SNS connected with 
non-osmotic vasopressin stimulation, but is also closely 
intertwined with the RAAS. The SNS interacts with the 
latter by stimulating the release of renin. Activation of 
the SNS also results in marked renal vasoconstriction 
through α-adrenoreceptor stimulation, further increasing 
renal arterial resistance while decreasing glomerular fil-
tration rate and renal blood flow [44]. This complex inter-
play between AVP, the SNS and the RAAS in the setting 
of arterial underfilling drives the emergence of an edema-
tous state. Furthermore, it serves as physiopathologi-
cal basis which reconciles the coexistence of increased 
ECFV and arterial underfilling or “effective hypovolemia” 
[45–47].
Plasma and urine osmolality: bedside calculation 
and laboratory assessment
Central to the interpretation of hyponatremia is the com-
parison of plasma and urine osmolality. Both plasma 
and urine osmolality may be measured by determin-
ing their freezing point. Given that the freezing point of 
a solution compared to distilled water is linearly related 
to its osmotic pressure, its osmolality is hence readily 
extrapolated. Osmometers are run through this princi-
ple and provide accurate assessment of plasma and urine 
osmolality [48]. Since serum osmolality measurement is 
seldom performed on a daily basis, multiple models for 
predicting plasma osmolality based on routine biochemi-
cal assessment have been proposed. The following equa-
tion has emerged as both the most widely used bedside 
calculation method and a robust determination of plasma 
osmolality [49]:
Boasting simplicity as one of its mains assets, this equa-
tion nonetheless carries several pitfalls. First, plasma urea 
is not an effective osmolyte in all other instances than 
severe renal failure. However its incorporation enhances 
the precision of the equation, when compared to plasma 
osmolality [49]. Second, whenever additional effective 
osmoles (whether endogenous or exogenous) are present, 
the calculated plasma osmolality is bound to be inferior 
to the measured osmolality, thus generating an osmolal 
gap (see below for details). Expressed otherwise, when 
a measured osmolality yields a low value, one is ascer-
tained that the patient’s patient plasma is hypoosmotic. 
In contrast, when faced with a low calculated plasma 
osmolality, a physician should rule out the possibility 
of an additional solute (a rare instance in clinical prac-
tice) before confidently reaching the same conclusion. 
In all other cases the formula produces results which 
fall within 5–10 mOsm of the measured osmolality [28]. 
POsmc = 2 × PNa + Plasma urea
+ Glycemia (units expressed in mmol/L)
POsmc = 2 × PNa + Blood urea nitrogen/2.8
+ Glycemia/18 (PNa expressed in mmol/L,
blood urea nitrogen and glycemia expressed
in mg/dL).
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Likewise, urinary osmolality may easily be inferred from 
simple biochemical assessment through the following 
equation [23]:
Similar to plasma osmolality calculation, solutes that 
have restricted permeability across the membrane of the 
distal nephron and collecting duct are accounted for in 
the calculation. With respect to urea, this assumption 
is only partly true. For reasons beyond the scope of this 
review, urea is indeed an effective osmole in the distal 
tubule. In the collecting duct, urea only fulfills this crite-
ria in two conditions, namely in the presence of AVP and 
when the rate of urine urea excretion is high [23].
Regulation of brain volume in response 
to hyponatremia
Hyponatremic encephalopathy
Since the brain is confined in an inextensible, rigid struc-
ture, cell volume regulation is crucial as any excessive 
increase in cell volume resulting in brain swelling over a 
threshold of 10 % equates with severely elevated intracra-
nial pressure, placing the patient at risk of serious brain 
injury and, ultimately, brain herniation [50, 51]. Fur-
thermore, the intracranial pressure–volume exhibits an 
exponential relationship so that even a minimal increase 
of the intracranial volume translates into a dangerously 
augmented intracranial pressure, once this threshold has 
been reached [52]. This tragic chain of events occurs if 
adaptive responses are overwhelmed and the “regulatory 
volume decrease” (as detailed below) mechanism fails to 
quell the increase in brain cell volume, such as in the set-
ting of profound and abrupt decrease of PNa levels. Brain 
edema causes the reduction of cerebral blood flow, which 
in turn results in cerebral ischemia, along with dimin-
ished cerebral spinal fluid production [53]. Accordingly, 
MRI imaging exhibits patterns suggestive of cytotoxic 
edema both in clinical and experimental conditions [54, 
55].
Focus on the relevant physiology: brain compensation 
mechanisms to hyponatremia
Conversely, if the fall in PNa levels is gradual, such 
as in the setting of chronic hyponatremia, the brain 
cells are able to elicit counteracting mechanisms in 
order to fend off any excessive water uptake. The 
most immediate response consists in the shifting of 
UOsmc = 2 × (UNa + UK) + Urine urea
+ Urine glucose (where UNa stands for
urinary sodium, UK for urine potassium,
units expressed in mmol/L)
UOsmc = 2 × (UNa + UK) + Urine urea nitrogen/2.8
+ Urine glucose/18 (units expressed in mg/dL).
liquid from the interstitial space to the cerebral spi-
nal fluid, a mechanism generated by the difference in 
hydrostatic pressure between the two compartments 
[56]. When glial cells are subjected to hypoosmotic 
stress, a swelling of these cells is initially observed. In 
fact, the influx of water across the blood–brain bar-
rier inside the astrocytes is likely to be facilitated by 
aquaporin water channels, namely AQP1 and AQP4 
[57, 58]. The pattern of AQP expression is restricted 
to astrocytes and ependymal cells, and they have 
been located predominantly in the foot processes of 
the former, at the interface of the brain and the major 
liquid compartments [59]. Consequently, water is 
routed selectively inside glial cells, thus sparing 
neurons from edema. Accordingly, AQP4-null ani-
mal models are protected against brain edema when 
challenged with hypoosmotic hyponatremia [60–62]. 
When placed in a hypoosmotic milieu, astrocytes are 
able to activate a mechanism known under the term 
of “regulatory volume decrease” which impedes the 
influx of water, regardless if the osmotic gradient 
is unfavorable. The first step of this adaptive pro-
cess requires the extrusion of inorganic ions by glial 
cells, primarily potassium (K+) and chloride (Cl−) 
and represents an energy dependant process pow-
ered by the Na+–K+-ATPase system [63]. However, 
this counter-regulatory mechanism wanes within a 
few hours with brain cells even gradually recovering 
their initial electrolyte content. In a second phase, 
the compensatory process involves mainly the extru-
sion of organic osmolytes which drives an obligatory 
efflux of water [64, 65]. In experimental studies, the 
loss of electrolytes accounts for more than 90  % of 
the osmotically active agents responsible for brain 
volume regulation over the first 24–48  h, thereaf-
ter the efflux process relies on organic osmolytes, in 
case hyponatremia is sustained [66]. The time lapse 
required for the brain to expel osmotic moieties also 
serves as a basis for discriminating between acute 
(<48  h) and chronic (>48  h) hyponatremia. The key 
role and nature of organic osmolytes involved have 
been highlighted in multiple in  vivo studies. They 
include myoinositol, taurine, glycerophosphoryl-
choline and glycerophosphoryl- ethanolamine, cre-
atine and phosphocreatine with various regional 
and temporal patterns depending on the experimen-
tal model and the type of organic osmolyte [50, 54]. 
Their delayed time course, in contrast to electro-
lytes, relates to the fact that transcription and trans-
lation of transporters and upregulation of synthesis 
enzymes of organic osmolytes represent an obliga-
tory and slow process before they can intervene in 
the cell volume regulation process [9].
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Risk factors associated with poor tolerance 
to hyponatremia
Accordingly, the two primary determinants which dictate 
the severity of hyponatremia-related symptoms are the 
level of hyponatremia and the rapidity of the fall of PNa 
levels. Life-threatening neurological symptoms are sel-
dom encountered when PNa levels are maintained over 
125 mmol/L. As outlined above, tolerance is expected to 
be poor whenever the decline in PNa levels outpaces the 
compensatory mechanisms. As a consequence, although 
there is no universal consensus regarding its definition, 
a PNa level inferior to 125  mmol/L, has recently been 
recognized as the biochemical threshold fulfilling the 
criteria for profound hyponatremia by two independent 
panels of experts [67, 68]. Next to these pivotal factors, 
other risk factors may aggravate the outcome of hypona-
tremia. For instance, young female patients are more 
inclined to develop severe neurological symptoms and 
seizures related to hyponatremia have been reported with 
PNa thresholds as high as 130  mmol/L. However, these 
cases mainly emanate from a single investigating team 
[69, 70] and the mechanisms responsible for this female 
preponderance have yet to be fully elucidated, although 
experimental studies have highlighted the synergistic 
and deleterious effects of vasopressin and estrogen on 
Na–K-ATPase activity in the CNS, a critical component 
of the adaptive response to hyponatremia of the brain 
[71, 72]. The co-occurrence of hypoxia along with severe 
hyponatremia also portends a poor prognosis and a pos-
sibly enhanced risk of permanent brain damage [69]. In 
experimental settings, animals manifest increased cer-
ebral edema and reduced cerebral perfusion as a result of 
the combined effects of hyponatremia and hypoxia. Fur-
thermore, hypoxia has been shown to suppress the com-
pensatory mechanisms elicited by hyponatremia [73]. 
More specifically, the Na–K-ATPase activity is virtually 
obliterated when a hypoxic insult is superimposed upon 
hyponatremia [74].
Osmotic demyelination
Overcorrection of hyponatremia and the risk of osmotic 
demyelination
By reviewing 12 cases of autopsy-proven cases of OD, 
Norenberg et  al. were the first to hypothesize a con-
nection between the overcorrection of PNa and the 
occurrence of OD [75]. In their landmark study, the 
PNa increased by at least 20  mmol/L over the course 
of 1–3  days prior to the emergence of the symptoms 
related to OD in all 12 patients. Experimental data [76, 
77] and other clinical series [78] soon confirmed this 
theory. Sterns, reporting on 8 patients with OD, showed 
that the PNa correction rate had exceeded 12  mmol/L/
day in all cases [78]. Focusing on patients with severe 
hyponatremia, further investigation from the same 
team yielded no case of OD, provided the PNa sus-
tained correction rates lower than 12  mmol/24-h and 
18-mmol/L/48-h [79]. Of note, patients presenting with 
profound (<120  mmol/L) and chronic (>48  h) hypona-
tremia also carry a greater potential for OD [70, 80]. 
However, since these results have been issued, there has 
been a steady stream of reports documenting cases of 
OD although the PNa correction rate was kept within 
these marks [81–86]. One important implication of these 
reports is the careful scrutiny of other risk factors for OD.
Pathophysiology of osmotic demyelination
The most prominent neuropathological finding in OD 
consists in the symmetrical destruction of myelin shafts 
and oligodendrocytes, perhaps through apoptosis, typi-
cally in the basis pontis [87, 88]. The inflammatory pro-
cess is at best limited to scatters of macrophages in the 
demyelinated area while neurons are usually spared until 
the advanced stages of the disease. The term central pon-
tine myelinolysis (CPM) refers to the preferential location 
of the disease and was devised after the description of the 
index case [89]. Why the pons is a privileged target for 
OD is certainly the result of its neuroanatomy: an intri-
cate network of gray and white fibers. As gray fibers are 
well endowed with capillaries, the adjacent white mat-
ter is thus vulnerable to circulating neurotoxic factors, in 
this case the osmotic gradient generated by a hasty rise in 
PNa [90]. The term is in fact misleading as areas from the 
CNS outside the pons are susceptible to OD. Extra-pon-
tine myelinolysis, which usually involves the sub-cortical 
gray matter may thus develop either concurrently with 
CPM (31 %) or may represent the exclusive manifestation 
of OD (22 %) [91]. Next to the pons, the most frequently 
described locations of OD involve the cerebellum, the 
lateral geniculate bodies, the external capsule, the hip-
pocampus, the putamen, the striatum and the thalami 
[92]. Many aspects of the physiopathology of OD are 
unsettled. It is believed that an overshoot in the correc-
tion of PNa is followed by a swift reaccumulation of elec-
trolytes (K+ and Cl−) which had initially been extruded 
by brain cells in a bid to offset brain edema in the early 
stages of hyponatremia [64]. At variance, a protracted 
lapse of time is mandated for these cells to regain their 
original levels of osmolytes [66, 93]. There is a good level 
of evidence suggesting that the disequilibrium between 
the levels of osmolytes and electrolytes is closely con-
nected to OD, but the precise sequence of events link-
ing this imbalance and the occurrence of demyelination 
is still under scrutiny. The breakdown of the blood–brain 
barrier is another characteristic feature of OD and restor-
ing its integrity using glucocorticoid therapy is known to 
mitigate OD in the experimental setting [94, 95]. How 
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OD may participate to the disruption of the blood–brain 
barrier and, reciprocally, how the latter may contribute 
to demyelination remain areas of speculation. Finally, the 
microglia, which infiltrates the areas of demyelination, 
has been entertained as yet another detrimental actor 
through the inflammation it generates [96, 97]. Experi-
mentally, reversal of its activation confers protection 
against demyelination [98, 99].
Other risk factors for osmotic demyelination
Strikingly, long before OD was recognized as a complica-
tion of the overcorrection of hyponatremia, investigators 
had noted that alcoholic patients were especially prone 
to this complication. In fact, three out of four patients 
from the original description of the disease were alcohol-
ics [89] and other series have reported rates of alcohol-
ism reaching 70  % [91]. Patients may even develop OD 
despite an optimal correction of hyponatremia or in the 
absence of preexisting plasma sodium disorders. In this 
case they usually disclose a history of alcohol abuse [100–
102]. The mechanism by which alcohol consumption 
favors the occurrence of OD is hitherto unknown. Like-
wise, malnutrition is also very prevalent among patients 
with OD [92].
Liver disease and liver transplantation represent potent 
risk factors for OD [103]. In that latter condition, up to 
3.5 % of patients have been reported to be affected by OD 
[104]. Furthermore, liver transplantation ranks third in 
term of comorbid condition associated with OD [105]. In 
this setting, OD is expected to occur early in the course of 
the patient’s post-operative management, usually within 
a week [106]. Liver transplantation is thought to give rise 
to an abrupt correction of preexisting hyponatremia thus 
paving the way for OD [104]. Calcineurin inhibitors, a 
cornerstone of patient’s immunosuppressive regimen in 
transplantation, possess neurotoxic effects on white mat-
ter, and may further potentiate the risk of OD [104].
Hypokalemia also predisposes to OD [107]. In reality 
it is potassium repletion, in case of coexisting hypoka-
lemia and hyponatremia, which carries the risk of OD 
[108]. Indeed, since PNa levels are determined by total 
exchangeable sodium and total body water but also by 
total exchangeable potassium [10], any potassium deliv-
ery to the patient will result in an increase in PNa levels, 
hence the risk of inadvertent PNa overcorrection if this 
phenomenon is not accounted for.
Conversely, uremia is believed to be at least partially 
protective against OD, probably because it enables the 
brain to reclaim organic osmolytes more swiftly [109]. 
In the experimental stage, uremic animals exhibit expe-
ditious recovery of myoinositol and other organic 
osmolytes, perhaps because in response to uremia brain 
cells exhibit enhanced organic osmolytes transport [109]. 
However the validity of this concept should be mitigated 
by the existence of several cases of OD in the setting of 
uremic patients undergoing hemodialysis [110, 111].
Clinical presentation of hyponatremia
Symptoms associated with hyponatremia
Clinical manifestations ascribable to hyponatremia 
are predominantly the expression of CNS dysfunc-
tion (see Table  1). The pattern of symptoms correlates 
with the level of hyponatremia and whether the dis-
order has developed rapidly or not [112, 113]. A panel 
of experts has recently proposed a biochemical grad-
ing of severity of hyponatremia [68]. It forms the basis 
Table 1 Clinical signs of hyponatremic encephalopathy and osmotic demyelination
a Neurological manifestations according to the severity of hyponatremia which is itself correlated to the magnitude and the rapidity of the fall in PNa
Hyponatremic encephalopathya Central pontine myelinolysis Extra-pontine myelinolysis
Mild hyponatremia Suggestive features Movement disorders
 Mild neurocognitive impairment  Quadriparesis/plegia  Extra‑pyramidal syndrome
 Gait impairment  Ataxia  Dystonia
Moderate hyponatremia  Nystagmus  Choreoathetosis
 Headaches  Dysarthria  Myoclonus
 Nausea  Ophthalmoplegia  Opsoclonus
 Emesis  Dysphagia  Akinetic‑rigid state
 Abdominal cramps  Pseudobulbar palsy  Akinetic mutism
Severe hyponatremia  “Locked‑in” syndrome Other symptoms
 Restlessness Associated neurological features  Emotional lability
 Lethargy  Impaired consciousness  Depression
 Confusion  Wernicke’s encephalopathy  Paranoia
 Coma  Disinhibition
 Seizure
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for the classification exposed herein below. In case of 
mild hyponatremia (PNa comprised between 130 and 
135  mmol/L), symptoms may be restricted to fatigue, 
mild cognitive and gait impairment [114]. Caution should 
be exerted before dismissing as asymptomatic patients 
with mild hyponatremia since a meticulous examination 
will in fact almost always unmask subtle neurocognitive 
deficiencies. Reciprocally, the existence of severe neuro-
logical symptoms in contrast with only mildly reduced 
levels of PNa should prompt physicians to consider 
other cause(s) of neurological impairment. In moderate 
hyponatremia (PNa between 125 and 130  mmol/L), the 
clinical picture is dominated by non specific symptoms 
including headaches, nausea, emesis and abdominal 
cramps. When confronted with profound hyponatremia 
(PNa <125  mmol/L), restlessness, lethargy, confusion, 
delirium but also coma, seizure and brain herniation 
with permanent brain damage and death are to be feared 
[112]. Furthermore, the course of the symptoms is largely 
unpredictable, and the patient’s clinical condition may 
swiftly deteriorate in the face of modest PNa decline. 
Accordingly, seizures are acknowledged to be the inaugu-
ral manifestation of hyponatremia [115] and they rank as 
one of the foremost cause of new-onset epilepsy on the 
ICU [116]. Extra-neurological consequences of hypona-
tremia comprise hypercapnic neurogenic respiratory fail-
ure which has been described primarily in young women 
in the post-operative setting [117].
Osmotic demyelination: clinical course
The clinical course is generally biphasic with inaugural 
symptoms of hyponatremic encephalopathy, as previ-
ously described, followed by a lucent interval of 1–7 days 
before clinical evidence of OD become manifest, but the 
onset has been reported to be delayed by as much as 
2  weeks. Signs distinctive of CPM include ataxia, nys-
tagmus, dysarthria, ophthalmoplegia, dysphagia, pseu-
dobulbar palsy, flaccid followed by spastic quadriparesis 
[118]. When it is full blown, CPM is characterized by the 
“locked-in” syndrome.
Depending on the brain region compromised by OD, 
various clinical patterns have been depicted (see Table 1).
Extra-pyramidal symptoms including dystonia, extra-
pyramidal rigidity and tremor have been the focus of 
reports as well as other movement disorders including 
choreoathetosis, myoclonic jerks and catatonia [119]. 
Cases of OD masquerading as parkinsonism have been 
recorded [119, 120].
Neuropsychological symptoms are frequently found 
and in as many as one patient out of four such symptoms 
may be the exclusive manifestation of OD [105]. Impaired 
consciousness and seizures are other salient features at 
presentation [121].
Of note, symptoms related to OD may be intertwined 
with other neurological syndromes complicating alco-
hol abuse, given the high prevalence of this condition in 
patients affected with OD, such as Wernicke’s encepha-
lopathy or Marchiafava–Bignami disease [91, 92].
In the setting of OD, MRI imaging will characteris-
tically exhibit a lesion with hyperintense changes on 
T2-weighted sequences accompanied by hypointense 
changes on T1-weighted sequences. Contrast enhance-
ment is most frequently absent. Importantly, a normal 
MRI imaging does not rule out the diagnosis of OD as the 
aforementioned findings lag behind the clinical onset of 
the disease [118, 122, 123].
The prognosis in terms of survival may not be as dis-
mal as previously reported. In a retrospective study on 
patients admitted in the ICU for OD, Louis et al. found a 
1 year mortality rate of 31 %, markedly below the mortal-
ity rates yielded by previous reports which approximated 
50 % [91, 124, 125]. Furthermore, 50 % of the surviving 
patients in this study had either recovered or sustained 
only mild forms of neurological disability, as assessed by 
the Rankin scale [124]. No clinical or imaging feature has 
been conclusively established as predicting the prognosis, 
although impaired consciousness upon initial presenta-
tion is usually associated with a poor outcome [121, 125]. 
Taken together, this data suggest that OD should not per 
se prompt intensivists to forego life-support measures.
Impact of hyponatremia on the outcome of ICU patients
There exist a fair number of converging studies indicat-
ing that hyponatremia is associated with a pejorative 
outcome among patients in the ICU (see Table  2 for 
details). Hyponatremia is an independent risk factor for 
shortened in-hospital survival [4–6, 126, 127] and a pro-
longed stay in the ICU [6]. Strikingly, it has been repeat-
edly demonstrated that the mortality risk is correlated to 
the magnitude of hyponatremia [4, 6, 126, 128] and that 
even mildly diminished levels of PNa portend a poor 
prognosis [126]. As for hospitalized patients in general, a 
greater proportion is destined to require ICU admission 
or mechanical ventilation during their management in 
case of documented hyponatremia upon admission [129]. 
This is not clear whether hyponatremia is merely a reflec-
tion of the severity of the underlying illness and associ-
ated comorbid conditions or if it directly influences the 
course of patients [51, 130].
Hyponatremia also exerts a negative impact on patient 
morbidity and mortality across various specific condi-
tions frequently encountered in the setting of the ICU. 
Patients admitted for community-acquired pneumonia 
often exhibit an AVP-dependent impairment of water 
excretion [131]. Furthermore, they fare worse whenever 
hyponatremia is present upon admission [132].
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In the context of heart failure, the co-occurrence of 
hyponatremia is consistently associated with protracted 
hospital stay [133] and predicts reduced short-term and 
long-term survival [134, 135]. Hyponatremia is also inti-
mately connected to advanced liver disease and a height-
ened mortality risk. Clinical studies have repeatedly 
pointed to hyponatremia as one of the culprits in the patho-
genesis of hepatic encephalopathy, possibly by thwarting 
the astrocytes compensatory mechanisms, including a 
depletion in brain osmolytes [136] and by generating a state 
of low-grade cerebral oedema [137]. Recently, in large ret-
rospective study in patients with chronic kidney disease, 
hyponatremia was found to be independently associated 
with increased mortality, irrespective of concomitant heart 
failure, and the survival rates of patients paralleled that of 
the sodium plasma levels [138].
In the field of neurological disorders, hyponatremia 
should not be dismissed as a benign finding, as even small 
decreases of PNa have been shown to be associated with 
a compromised prognosis. As a matter of fact, hypona-
tremia has been proven an independent predictor of 
mortality in various settings such as patients with stroke 
[139], adults with tuberculous meningitis [140] and chil-
dren affected with pneumococcal meningitis [141]. As 
for patients with sub-arachnoid hemorrhage, the risk of 
vasospasm is increased whenever hyponatremia coexists 
[142]. This is not surprising given the exquisite sensitiv-
ity of the brain to elevated intracranial pressure, the latter 
being (negatively?) impacted by hyponatremia.
Etiologic diagnosis
Etiologic diagnosis strategy and conditions associated 
with hyponatremia
Unraveling the cause(s) of hyponatremia requires a 
sequential approach as depicted in Figs.  1 and 2. The 
algorithm depicted in Fig. 2 is based on published works 
and guidelines [143, 144] and studies have confirmed its 
appropriate diagnostic accuracy [145] provided that a 
meticulous step by step analysis is performed and that 
physicians are aware of some of its pitfalls [145]. How-
ever, physicians should not be deterred by the appar-
ent complexity of the algorithm. As highlighted in the 
following sections, most of the issues derived from it 
can be solved at the patient’s bedside, the great bulk of 
patients belong to the subgroup exhibiting hypotonic 
hyponatremia and those with ill-tolerated hyponatremia 
either retain a normal ECFV or display a diminished 
ECFV.
Hyponatremia in the setting of normal or increased 
tonicity
As Na is the preponderant solute in the extracellular 
fluid, PNa also serves as the prime determinant of serum 
tonicity. It follows that hyponatremia almost universally 
indicates a state of hypotonicity. In other words, the vast 
majority of cases of hyponatremia (especially when pro-
found) are hypoosmotic hyponatremia, a term largely 
preferable to the so-called “true hyponatremia”. However, 
two exceptions to this rule may be delineated.
Fig. 1 Key points when managing severe hyponatremia in the ICU. Asterisk in the absence of concurrent increased EFCV. a A rare instance in routine 
clinical practice. b  High water intake along with increased AVP levels may coexist. CKD chronic kidney disease, SIADH syndrome of inappropriate 
antidiuretic secretion, NA+uurine sodium concentration
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Spurious isotonic hyponatremia or so‑called 
“pseudohyponatremia”
Cell hydration and volume is not affected in this condi-
tion. Spurious isotonic hyponatremia represents a phe-
nomenon which arises in case of a major increase of 
the solid fraction of the plasma stemming from either 
a major increase of lipids or proteins. As a result, the 
plasma water fraction is contracted and the PNa level 
may deceivingly appear to be lowered. Hence the confus-
ing term “pseudohyponatremia” which is meant to allude 
to the fact that the intracellular volume is sustained 
despite lowered PNa values. As a result, neurological 
symptoms should not be interpreted as a manifestation 
of the diminished levels of PNa. They are in fact more 
likely be related to hyperviscosity. The phenomenon of 
isotonic hyponatremia (“pseudohyponatremia”) can be 
suspected very easily from the outset simply by concur-
rently measuring the levels of protein levels and by pay-
ing attention to the serum’s aspect: in the background of 
hypertriglyceridemia, it will almost certainly appear to 
be opalescent. Indeed, noticeable isotonic hyponatremia 
is solely observed when protein or lipid concentrations 
are extraordinarily high. Alternatively, the genuine levels 
of PNa can be deduced by simple computations. In fact, 
this pitfall is uncovered in most hospitals because PNa 
levels are assessed by using direct ion-selective electrode 
for measuring PNa levels instead of indirect ion-selective 
electrode. The latter method, resorts to a dilution phase, 
as assumes a constant non-water fraction of 7 %. It fol-
lows that indirect ion-selective electrode measurements 
will provide a factitious decrease in PNa levels when the 
solid component of serum is augmented, at variance 
with direct ion-selective electrode testing which do not 
require pre-analytic dilution and takes into account the 
variable volume share in lipids and colloidal proteins 
with respect to total plasma volume. [146, 147].
Hypertonic hyponatremia
The intracellular compartment is dehydrated and its vol-
ume decreased in this condition. Hyponatremia with 
increased osmolality is to be considered when com-
pounds other than sodium, whether endogenous or exog-
enous, create an osmotic drive causing the relocation of 
water from the intracellular compartment to the extracel-
lular compartment.
Hyperglycemia, such as found in ketoacidosis and the 
hyperglycemic hyperosmolar state is the best known 
cause of hyponatremia in relation with endogenous com-
pounds. When there is a severe degree of hyperglycemia, 
in the absence of insulin, this causes a rise in the plasma 
osmolarity thus forcing water to shift from the intracellu-
lar compartment to the extracellular compartment [148, 
149]. This relocation of the water content explains the 
observed fall of PNa, a situation typical of hyperosmotic 
hyponatremia.
Of note, the works of Katz et al. have popularized the 
use of a correction formula which predicts a 1.6 mmol/L 
reduction in PNa levels whenever the glucose lev-
els increases by 5.6  mmol/L [150]. This computation 
should nonetheless be handled with care as it may tend 
Fig. 2 Etiological diagnostic strategy. CKD chronic kidney disease, SIADH syndrome of inappropriate antidiuretic secretion, Na+u  urine sodium 
concentration. a A rare instance in routine clinical practice. b High water intake along with increased AVP levels may coexist. Asterisk in the absence 
of concurrent increased EFCV
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to depreciate the true drop in PNa and another correc-
tive computation has been devised [23, 151]. In order 
to circumvent this pitfall, plasma osmolarity should be 
the preferred monitoring parameter during the patient’s 
management, as PNa may appear to increase while in fact 
plasma osmolarity is undergoing an expeditious decline, 
as glucose levels fall.
The post‑ transurethral resection of the prostate (TURP) 
syndrome
Examples of exogenous “effective osmoles” include gly-
cine, mannitol and sorbitol. The “post-TURP syndrome” 
represents yet another well recognized condition where 
the presence exogenous osmoles (glycine, mannitol and 
sorbitol) give rise to hyponatremia. Indeed, during post-
transurethral resection of the prostate (TURP), it is cus-
tom to instillate a solution of hypotonic fluids containing 
any of the aforementioned solutes though a Foley cath-
eter for electrocoagulation purposes. These irrigation 
solutions were designed to replace distilled water, the 
reabsorption of which caused massive hemolysis and 
acute kidney injury [152]. However, in case the poste-
rior wall of the prostate is breached or a venous plexus 
is severed during surgical manipulations, the ensuing 
intraperitoneal extravasation of the irrigation fluid, or its 
direct reabsorption in the circulation, may cause acute 
hyponatremia in the face of an osmolality which varies 
over time from hyper to hypoosmolality [153]. Indeed 
two sequential mechanisms concur to determine hypona-
tremia: (1) glycine and sorbitol are initially restricted in 
the extracellular compartment, at least in the very early 
stages following the administration of the lavage fluids. 
Both particles are osmotically active and thus prompt 
water to shift from the intracellular compartment into the 
extracellular compartment thus causing hyponatremia. 
(2) Glycine and sorbitol penetrate into cells within two 
hour following the administration of lavage fluids where 
they are metabolized. (3) The net balance at this time 
point is a sheer gain of water along with hypoosmotic 
hyponatremia. Brain swelling may now ensue, potentially 
jeopardizing the patient’s neurological status [23, 154]. By 
contrast, mannitol does not undergo cell metabolization 
and promotes hyponatremia through direct osmotic or 
“translocational” effect with no concurrent major change 
in plasma osmolality [155, 156]. Although the setting is 
usually sufficiently suggestive to prompt the diagnosis, 
the osmolar gap may be a helpful adjuvant in unmasking 
the presence and indirectly determining the concentra-
tion of the solute used. If the irrigation solution contains 
glycine, severe encephalopathy is to be feared, as gly-
cine metabolism yields ammonemia [157]. Since its first 
description in the post-operative course of TURP, similar 
complications have been described following in a wide 
range of endoscopic surgeries [156].
In “conclusion”, although the multiplicity of etiologies 
and the somewhat intricate nature of mechanisms related 
to normotonic or hypertonic hyponatremia may seem 
bewildering at first, physicians may salvage consolation 
in the fact that these conditions are rare, cause only mild 
to moderate hyponatremia and can be readily ruled out 
by a simple and expeditious clinical and biological assess-
ment. Once the diagnosis of hypotonic hyponatremia is 
ascertained, several steps must be undertaken in order to 
elucidate the precise mechanism of this disorder.
Hyponatremia and hypotonic urine: look out for hypotonic 
fluid intake
The next phase is to evaluate urine tonicity on order 
to discriminate patients with impaired urine diluting 
mechanisms, a vast majority of patients in the ICU, from 
the small subset of patients who retain diluting abilities 
[3]. In the event of hyponatremia, renal urinary diluting 
capacities are usually deemed satisfactory whenever the 
urinary osmolality is inferior to that of plasma and, at 
best, if urine osmolality does not exceed 100  mOsm/kg 
[145].
Hypotonic hyponatremia in association with hypo-
tonic urine is strongly suggestive of an excessive water 
intake, including psychogenic polydipsia, a psychiatric 
disorder which may affect up to 25  % of patients diag-
nosed with schizophrenia [158]. Given that in physi-
ological conditions, and provided that patients are on a 
normal diet, the kidneys boast a maximum excretory 
capacity of 10–15 L/day it is unlikely that polydipsia per 
se is sufficient to induce hyponatremia, even when vast 
amounts of hypotonic fluids are ingested by the patient. 
In fact, clinical investigations have pointed out subtle 
defects in the maximum urinary dilution and free water 
clearance in patients with polydipsia and hyponatremia, 
perhaps in relationship with an enhanced sensitivity to 
arginine vasopressin [147, 148]. What’s more, polydip-
sic patients exhibit increased thirst across a wide range 
of osmolality, compared to controls [148]. The under-
lying mechanisms responsible for these alterations in 
water homeostasis remain to be unfolded, yet hypona-
tremic polydipsic schizophrenic patient display structural 
changes and neuroendocrine impairment affecting the 
anterior hippocampus which may serve as an anatomi-
cal substract for future investigations [149, 150]. Finally, 
an additional level of complexity arises from the comor-
bidities and therapies frequently associated with schizo-
phrenia which may be involved in the pathogenesis of 
hyponatremia, first and foremost being the prescription 
of antipsychotic and antidepressant [151].
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In a similar vein, “beer potomania” may also result in 
hyponatremia together with lowered urine osmolality. 
In this condition, patients typically have a history of low 
solute intake and a diet deprived of protein whereas they 
ingest vast amounts of beer, a largely hypotonic bever-
age. Consequently, these patients are unable to produce 
the osmolar load which drives the free-water excretion 
in physiological conditions [159]. In the face of large 
volumes of hypotonic fluid intake, this equates with 
hyponatremia. A situation that can be very much likened 
to beer potomania is the “tea and toast” syndrome. Simi-
lar to potomania, patients –almost universally elderly, 
incapacitated subjects- are fed on low protein diet 
(“toasts”), only in this case the hypotonic beverage con-
sists in tea.
Hyponatremia with impaired urinary dilution: assess the 
patient’s extracellular fluid volume status
Once the previous steps have been cleared, the most 
plausible case-scenario left is hypoosmotic hypona-
tremia along with non-maximally diluted urine. In these 
circumstances, a defect in tubular diluting functions, 
caused by the secretion of AVP, is likely to underpin 
the occurrence of hyponatremia and urine osmolality is 
typically expected to be superior to plasma osmolality. 
Notable exceptions to this interpretation include condi-
tions which interfere with normal tubular function with 
the most prominent examples being the use of thiazide 
diuretics and severe kidney disease. Finally a urinary 
osmolality superior to 100 mOsm/kg, but inferior to that 
of the plasma frames an area of uncertain interpretation. 
In this case, both high water intakes along with low sol-
ute intake may coexist with excessive vasopressin action 
[68, 160].
The clinical conundrum can thereafter be restated as 
follows: what is the mechanism that drives the secretion 
of AVP? Assessment of ECFV is of paramount impor-
tance and may provide meaningful insights to that ques-
tion. It should include a gross appreciation of the total 
body sodium stores and sources of hypotonic fluids 
intake, including of iatrogenic origin. Most of all it should 
allow for the discrimination of 3 subsets of patients with 
decreased, increased or normal ECFV. In patients with 
decreased ECFV, AVP production is directly induced by 
the hemodynamic stimulus resulting from “true hypo-
volemia”. As for patients with increased ECFV, a cat-
egory largely dominated by conditions related to heart 
failure or cirrhosis, “effective hypovolemia” provides the 
grounds for increased AVP secretion. Finally, in euv-
olemic patients, AVP secretion is unconnected to its 
usual physiological triggers.
Hyponatremia with normal ECFV overlaps extensively 
with the syndrome of inappropriate antidiuretic (AVP) 
hormone secretion. In order for this diagnosis to be con-
templated the following criteria should be fulfilled: hypo-
tonic hyponatremia, urine osmolality in excess of plasma 
osmolality, euvolemia, and normal renal and adre-
nal function [161]. However distinguishing euvolemic 
patients from mildly hypovolemic patients based solely 
on clinical grounds is notoriously challenging [145, 162, 
163].
Dosing AVP is of limited usefulness, as the levels of 
plasma of AVP have been proven to fluctuate unpre-
dictably and are often augmented in patients with 
both true hypovolemia (decreased ECFV) and effective 
hypovolemia (increased ECFV), as a result of a non-
osmotic stimulus, as well as in the syndrome of inap-
propriate antidiuretic hormone secretion (SIADH), 
which remains in essence, a diagnosis of exclusion. 
Nevertheless, other biological features may represent 
a valuable aid for physicians investigating the presence 
of SIADH. They include lowered plasma uric acid and 
blood urea nitrogen, and failure to correct PNa levels 
following the infusion of 0.9  % saline solution [144, 
164]. Uric acid stands out as, perhaps, the most use-
ful static biological parameter. Reduced levels of uric 
acid levels are thought to result from the mild volume 
expansion which occurs at the onset of SIADH, as well 
as from increased urinary excretion [165, 166]. How-
ever, the coexistence of hyponatremia and lowered uric 
acid levels may also be witnessed in other conditions 
unrelated to SIADH such as the use of diuretics, poto-
mania and cirrhosis [166, 167].
When the physician feels unconfident whether the 
patient’s ECFV status is normal or decreased, a simple 
diagnostic test consists in the infusion of 0.9  % saline 
(NaCl) solution. In the event of SIADH, the infusion 
of the 0.9  % NaCl solution will not ameliorate and may 
even worsen PNa levels, and, in any case, an immediate 
rise in natriuresis will be observed. This phenomenon 
which goes by the name of “desalination” describes the 
process whereby following the administration of isotonic 
saline fluids and due to the action of AVP, the sodium 
load is excreted in hypertonic urine while the free water 
content is reabsorbed in the patient’s body. Conversely, 
the administration of a 0.9  % NaCl solution will tend 
to normalize the PNa in hypovolemic patients, with no 
appreciable and immediate modification of the urinary 
concentration in sodium, until ECFV is restored. There-
after, a delayed rise in sodium excretion in order to bal-
ance sodium intake will be manifest [168]. Nevertheless, 
physicians will find consolation in the fact that patients 
admitted in the ICU for profound and/or severe symp-
tomatic hyponatremia are bound to display obvious 
abnormalities of the ECFV status, whether increased or 
decreased.
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Patients with normal ECFV: when should SIADH be 
suspected?
Pathophysiology of  SIADH In this setting, the primary 
physiopathological mechanism responsible for hypona-
tremia is the disconnection of AVP secretion from its usual 
osmotic and hemodynamic stimuli. AVP triggers water 
reabsorption via the collecting ducts, thus promoting a 
state of body water overexpansion which, in turn, leads 
to hyponatremia by dilution of the plasma PNa content. 
Patients suffering from SIADH are devoid of overt signs of 
hypervolemia because compensatory mechanisms aiming 
at restoring a normal extracellular fluid volume are elic-
ited [169]. The pivotal mechanisms consist chiefly in the 
augmented secretion of atrial natriuretic peptide and the 
suppression of renin and aldosterone secretion [170]. The 
net effect is a transient negative sodium balance due to a 
transient increase in natriuresis (in order to restore a nor-
mal ECFV but at the expense of lowered tonicity).
At a later stage, a down-regulation of AVP receptors 
at the surface of the collecting ducts blunts the response 
to increased AVP levels, a phenomenon acknowledged 
under the term of “AVP antidiuresis escape” [171, 172]. 
Consequently, this intricate interplay between AVP secre-
tion, AVP-resistance and natriuresis allows PNa to settle 
at a steady level and to sustain euvolemia (See Table 3). 
Since its description in 1957 in two patients with bron-
chogenic carcinoma [173], SIADH has been described 
as an epiphenomenon of a broad range of conditions 
and diseases which are recapitulated in Table  3. Finally, 
there is an ever-expanding list of agents that may cause 
hyponatremia through various SIADH-related mecha-
nisms, namely by enhancing the release of AVP (neuro-
leptics, anti-depressant drugs and anti-neoplastic drugs), 
by potentiating (carbamazepine), or even by mimicking 
its action on collecting ducts (oxytocin) [174].
Endocrine disorders and  inappropriate AVP secre‑
tion Before claiming that a patient’s low level of PNa 
may be imputed to SIADH, one must keep in mind that 
various endocrine disorders induce hyponatremia the fea-
tures of which may masquerade as SIADH, at least at first 
glance. Hypothyroidism has long been viewed as a potent 
cause of hyponatremia which is regarded as one of the 
prime features of myxoedema coma [175, 176]. Mecha-
nistic features suggestive of SIADH including impaired 
urinary dilution, failure to excrete large volume of free 
water have and, in some cases, reports of elevated AVP 
plasma levels have reinforced this notion. The relevance 
of hypothyroidism-induced hyponatremia has, however, 
recently been challenged by clinical studies which did not 
find any significant association between the two clinical 
entities, at least in the mild form of this endocrinopathy 
[177]. Therefore, one should not ascribe hyponatremia 
to hypothyroidism before other causes of hyponatremia 
have been carefully scrutinized. Patients affected with iso-
lated glucocorticoid deficiency, a hallmark of hypopituita-
rism, usually retain a normal volemic status, in contrast to 
patients with primary adrenal insufficiency. Yet, hypona-
tremia is a frequent finding in these cases [178] and its 
biochemical characteristics may prove to be indistin-
guishable from those of SIADH [179]. Both AVP-depend-
ent and AVP-independent pathways have been postulated 
as the possible mechanism underlying hyponatremia in 
these cases [180, 181].
Inflammation as  a potent stimulus for  AVP release In 
the post-operative setting, patients often cumulate vari-
ous risk factors placing them at high risk for the develop-
ment of SIADH. Nausea, pain, hemodynamic instability, 
neurological and pulmonary insults are believed to act as 
non-osmotic stimuli which enhance the release of AVP 
and may even prevail over AVP-inhibition generated by 
an hypoosmotic state [182–184]. Additionally, there has 
been mounting evidence that the key pro-inflammatory 
cytokine IL-6 may serve as the missing link between states 
Table 3 Causes of SIADH
AVP arginine vasopressin, SCLC small cell lung cancer, SAH subarachnoidal 
hemorrhage, TCC tricyclic antidepressant, MAOI monoamine oxydase inhibitor 
antidepressant, SSRI selective serotonin uptake inhibitor antidepressant
Paraneoplastic production 
of AVP
Eutopic production of AVP/ 
enhanced hypothalamo– 
pituitary release of AVP
SCLC non‑SCLC CNS disorders
Head and neck cancer  Infectious: meningitis,  
encephalitis, brain abscess
 Mesothelioma  Vascular: SAH, subdural  
hematoma, thrombosis
 Stomach carcinoma  Multiple sclerosis
 Duodenum carcinoma  Acute intermittent porphyria
 Thymoma  Guillain‑Barré syndrome
 Lymphoma  Shy‑Drager syndrome
 Olfactory neuroblastoma  Schizophrenia
 Bladder carcinoma Pulmonary disorders
 Sarcoma  Pneumonia, tuberculosis
Potentiation of AVP effects  Pneumothorax, atelectasis
 Carbamazepine  Asthma, cystic fibrosis
 Sodium valproate  Positive pressure ventilation
 Cyclophosphamide Drugs
 Neuroleptics
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of systemic inflammation, a hallmark of post-operative 
patients, and the release of AVP and subsequent hypona-
tremia [185, 186]. IL-6 deficient mice exhibit reduced 
expression of AVP [187]. Ghorbel et al. were able to dem-
onstrate that IL-6 is not only largely co-localized in the 
SON and PVN but its expression is upregulated in set-
tings of potent AVP stimulation such as dehydration [188]. 
Finally, by injecting a recombinant form of this cytokine 
to human volunteers, a team of investigators were able 
to establish that IL-6 exerts secretagogue action on PVN 
AVP secretion [189]. Pathways connecting IL-6 to vaso-
pressin release are still under scrutiny but IL-6 has been 
shown to be capable of crossing the blood brain barrier. 
Alternatively, other cytokines may elicit the secretion of 
IL-6 by blood brain barrier cells [185]. Either way, these 
observations set the frame for a novel non-osmotic, non-
hemodynamic stimulation of AVP secretion. In contrast, 
other ICU-associated stressful conditions do not interfere 
with water excretion and the sole admission in ICU may 
not be incriminated per se in the occurrence of SIADH 
and hyponatremia [184]. Finally, elderly patients warrant 
special attention as old age predisposes to the develop-
ment of SIADH [190, 191]. More specifically, the latter 
may only be unveiled when the patients are exposed to 
high volumes of hypotonic fluids.
Exercise‑induced hyponatremia Hyponatremia is 
common among subjects submitted to strenuous exer-
cises. In one study, 13 % of marathon runners presented 
with hyponatremia and 0.6  % had severe hyponatremia 
(120 mmol/L or less) [192]. Weight gain, a plausible reflec-
tion of the volume of potential overhydration is a strong 
predictor of the occurrence of hyponatremia as well as 
female gender and the duration of exercise [193]. Widely 
viewed as a consequence of excessive sodium and chlo-
ride loss through sweating, hyponatremia, in fact, fulfills 
the criteria for SIADH [194, 195]. It has been postulated 
that IL-6, a cytokine released in this case as a consequence 
of muscle glycogen depletion following prolonged racing, 
may serve as a trigger for non-osmotic AVP secretion 
[185, 196].
Hyponatremia in the setting of increased ECFV
Three subsets of conditions may be delineated, when con-
fronted with hyponatremia in the context of increased 
ECFV. Urinary sodium levels (<20 mmol/L), which mir-
rors secondary hyperaldosteronism and enhanced tubu-
lar sodium reabsorption, should prompt a high index 
of suspicion with regards to heart failure, cirrhosis and 
nephrotic syndrome [197].
There is a common ground between heart failure, cir-
rhosis and nephrotic syndrome with respect to the mech-
anisms implicated in the development of hyponatremia, 
namely a state of arterial underfilling which results, as the 
physiopathological scenario unfolds (see “Basic princi-
ples of sodium and water equilibrium”), in an increased 
release of AVP, an augmented adrenergic drive and the 
stimulation of the plasma renin angiotensin aldosterone 
system [12, 46, 198–200].
In cirrhosis, as in heart failure, arterial underfilling, 
and its ensuing consequences, are also the predominant 
hypothesis behind the physiopathology of hyponatremia 
[201]. The difference lies in what causes arterial under-
filling, namely splanchnic arterial vasodilatation, itself a 
consequence of increased nitric oxide production in the 
setting of advanced cirrhosis.
The incidence of hyponatremia is reputed a less com-
mon accompaniment of nephrotic syndrome than other 
oedematous states [27]. Hyponatremia has also been 
interpreted as the expression of arterial underfilling by 
virtue of Starling’s principle. More specifically, fluid is 
thought to translocate from the vascular space to the 
interstitial space, a phenomenon elicited by the decline 
in oncotic pressure, thereby lowering the effective arterial 
blood volume. In line with this, physiological investiga-
tions in children with nephrotic syndrome have revealed 
elevated levels of AVP [202]. However, this theory is 
undermined by conflicting results regarding the level of 
effective arterial blood volume in nephrotic patients and 
the numerous flaws attached to Starling’s principle [203].
Hyponatremia and decreased ECFV
First of all, it should be kept in mind that hypovolemia, 
irrespective of its cause, is a powerful inductor of AVP 
release so that any concomitant input of hypotonic flu-
ids is bound to generate hyponatremia. In other word, 
hyponatremia is likely to be both “dilutional” and “deple-
tional” even in the face of overt sodium wasting and these 
terms should be abandoned.
Broadly speaking, patients can be categorized either 
as having sodium losses via the kidney (diuretics, adre-
nal insufficiency, salt-wasting nephropathies and the so-
called cerebral salt-wasting syndrome) or through the 
digestive tract.
Measuring the sodium urine concentration may pro-
vide clues to which is the route involved in sodium wast-
ing (see Fig. 2). Typically, when hypovolemia arises from 
digestive losses, urinary sodium is expected to be low 
(<20 mmol/L), as a result of secondary hyperaldosteron-
ism. One exception to this rule is hyponatremia related 
to vomiting. In this case, bicarbonate urinary excretion 
is increased in order to counteract the state of metabolic 
alkalosis that results from gastric losses of hydrochloric 
acid. Renal excretion of sodium ensues as bicarbonaturia 
requires the concomitant excretion of a cation. Another 
caveat comes from the usage of diuretics which will 
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increase the urinary sodium concentration rendering its 
interpretation challenging.
Thiazide diuretics have carved out a preponder-
ant position in the therapeutic arsenal against arterial 
hypertension thanks to clinical trials which have estab-
lished their efficacy [204]. Along with their popular-
ity thiazides have also unfortunately rose to become the 
leading cause of drug-induced hyponatremia [205]. Thi-
azide diuretics primarily act by inhibiting the transport 
of sodium and chloride in the distal convoluted duct and 
connecting segment. This impedes the lowering of the 
tubular fluid osmolarity to its minimum value and, con-
sequently, reduces electrolyte-free water excretion [206, 
207]. Besides hampering the tubules diluting capacity, 
thiazides also induce potassium depletion, another fac-
tor propitious to the development of hyponatremia, 
given that PNa levels are correlated to the total exchange-
able potassium [10]. In other words, a contraction of the 
potassium pool is per se sufficient to explain the occur-
rence of hyponatremia, in agreement with Edelman’s 
equation. Finally, thiazide-induced volume depletion is 
mild and, in any case, delayed, so that it is not likely to 
be a major player in the pathogenesis of hyponatremia. 
At variance, loop diuretics represent a relatively infre-
quent cause of hyponatremia [208]. Their action is short 
lived allowing for repletion of sodium stores. Most of all, 
loop diuretics alter concentration abilities as well to dilu-
tion abilities, in contrast to thiazide diuretics which only 
affect the latter [207].
If hyponatremia does not reliably predict relative adre-
nal insufficiency in critically ill patients [209], it is a sali-
ent feature of primary adrenal insufficiency [210, 211]. 
In this context, hyponatremia stems from both the loss 
of glucocorticoid and mineralocorticoid functions. 
However, hypovolemia reflects the mineralocorticoid 
deficiency which manifests itself by depressed levels of 
aldosterone and ensuing urinary sodium wasting. In 
these conditions, water will be maximally retained and 
hyponatremia will ensue.
Cerebral salt-wasting syndrome (CSW) remains at 
this time a controversial entity and its very existence has 
fuelled debate, some authors considering this entity as a 
misnomer for SIADH [212]. To qualify for salt-wasting 
syndrome, patients must display signs of reduced extra-
cellular volume along with inappropriate sodium losses 
[173, 213] in the presence of a cerebral insult, predomi-
nantly subarachnoid hemorrhage [214]. However, an 
inadequately elevated natriuresis and a context of a cen-
tral nervous lesion are not distinctive of SIADH, so that 
to differentiate CSW from SIADH one has to rely on the 
assessment of extracellular volume, a difficult task in rou-
tine practice as previously outlined. Regarding its biologi-
cal characterization, yet another caveat lies in the fact that 
reduced uric acid levels may be found in patients with 
presumed CSW, similar to SIADH, perhaps as a conse-
quence of defective tubular reabsorption of uric acid [213, 
215]. Nevertheless, studies resorting to isotopic deter-
mination of extracellular volume have hypothesized that 
CSW might be more prevalent in the setting of neuro-
surgical ICU than is SIADH [216, 217]. The pathogenesis 
of CSW remains elusive. Some have surmised that CNS 
damage caused a breakdown in the sympathetic-mediated 
stimulation of renin secretion by the juxtaglomerular 
cells, thereby leading to diminished levels of aldosterone 
and a reduction of sodium reabsorption in the collecting 
duct [218, 219]. One major shortcoming associated with 
this theory is that a surge in the adrenergic tone, rather 
than a decrease in sympathetic activity, has been reported 
in acute CNS disease or injury. In fact, this serves as a 
basis for an alternative physiopathological hypothesis to 
CSW; the increase in sympathetic activity may stimulate 
the secretion of brain natriuretic peptide (BNP) secretion 
by the myocardial tissue [220]. In conclusion, this diag-
nosis must be envisaged with caution. Its distinction with 
SIADH remains elusive and, in any case, hypertonic saline 
solution administration under strict monitoring is man-
datory [212], together with tight hemodynamic and bio-
logical monitoring (PNa, natriuresis, renal function).
Salt-wasting nephropathies encompass multiple het-
erogeneous and unrelated kidney diseases, most of which 
are anecdotal causes of hyponatremia. They include con-
genital obstructive uropathy [221], cisplatin-induced 
nephropathy [222], interstitial nephritis [223], medullary 
cyst disease [224] and salt-wasting tubulopathies (con-
genital or acquired type I pseudo-hypoaldosteronism 
[225], Bartter and Gitelman syndromes).
The management of hyponatremia
The principles of PNa correction in case of severe 
hyponatremia and hyponatremic encephalopathy
Profound hyponatremia with concurrent severe neuro-
logical symptoms is a medical emergency and warrants 
prompt therapy. The pivotal treatment is hypertonic 
saline (3 % NaCl, 513 mmol/L) delivered intravenously. 
0.9 % NaCl is not an appropriate solution as its tonic-
ity is insufficient to ensure an adequate raise of PNa 
levels. Volume overload is an obvious contraindica-
tion to hypertonic saline therapy, but the great bulk of 
patients managed for profound, symptomatic hypona-
tremia usually display normal or diminished ECFV. 
Administration through a nasogastric tube should be 
avoided because enteral absorption is impaired and 
unpredictable in critically ill patients. In contrast, both 
continuous intravenous and bolus therapy are accept-
able administration modalities. The optimal magni-
tude of increase in PNa is hitherto unknown, varies 
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according to experts and proposed aims, does not rely 
on sound evidence or is based on studies in other 
settings [226]. For instance, in the context of brain 
injury, a 4  mmol/L increase in PNa levels resulted in 
significantly diminished intracranial pressure [227]. 
In a retrospective assessment of 60 children suffering 
from hyponatremic seizures, investigators concluded 
that a 3–5  mmol/L rise in PNa was enough to termi-
nate seizure [228]. Consistently, recent guidelines 
have advocated a rapid 4–6  mmol/L increase in PNa 
levels (which equates to an increase of 8–12  mmol/L 
in effective osmolality) as a reasonable target [70, 229, 
230]. Likewise, the rate of PNa correction rate has 
fuelled much debate [231] and it does not lend itself 
well to straightforward computation [230]. Nonethe-
less, a consensus for a rapid, albeit time-limited rise 
in PNa has surfaced. In agreement with this concept, a 
mean correction rate of 1.3 mmol/L/h resulted in sat-
isfactory outcome among 33 patients, among which 12 
presented with coma [232]. Therefore a correction rate 
of 1.5–2  mmol/L/h appears to be safe and effective, 
provided it is restricted to the first 3–4 h following the 
initiation of the hypertonic saline therapy [229]. As a 
rule of thumb, a single bolus of 2  cc/kg of 3  % NaCl 
yields an increase of PNa approaching (but inferior) 
to 2 mmol/L [226]. More sophisticated formulae have 
been devised to predict the increase in PNa following 
sodium repletion, one of the most popular being the 
so-called Adrogue–Madias equation [113]. Great cau-
tion should be exercised when resorting to these com-
putations as they have been found to underestimate 
the true magnitude of PNa increase [233]. Notably, the 
Adrogue–Madias formula relies on the gross assump-
tion that the total body water content is constant and 
discards ongoing sodium, potassium and water losses 
as well as spontaneous correction [234]. In any case, 
a close monitoring of PNa levels is mandatory and 
should be repeated every 2 h.
Loop diuretics which promote enhanced electrolyte-
free water excretion may be useful, especially in the 
setting of coexistent fluid overload and in SIADH. Nota-
bly, one study established that urine sodium averaged 
60  mmol/L (±47  mmol/L) after furosemide therapy 
indicated for heart failure [235]. With respect to SIADH, 
this condition forms the only acceptable reason to con-
currently administer sodium (which will allow for a brisk 
increase PNa levels) and diuretics (that help eliminating 
free water, thus bolstering the rise in PNa levels).
Finally, a meticulous scrutiny for evidence of hypoxia 
and seizures is mandatory as both may aggravate cerebral 
edema. Practitioners should resort liberally to mechani-
cal ventilation in case of any one of these complica-
tions occurs yet the utmost care should be taken when 
performing endotracheal intubation to avoid hypoxemia 
during this procedure. At variance, anticonvulsant ther-
apy is seldom efficacious [228].
Exercise-associated hyponatremia has been the object 
of guidelines [236]. Intravenous normal saline (0.9  % 
NaCl, 154 mmol/L Na+) administration runs the risk of 
further aggravating hyponatremia given that AVP levels 
are bound to be very elevated in this setting. Thus only 
athletes exhibiting clear signs of decreased ECFV are 
likely candidates for this therapy [193, 237]. Hypertonic 
3 % saline therapy through intravenous administration is 
the safest option whenever participants exhibit profound 
hyponatremia and/or neurological symptoms [236–238]. 
Experts have advocated the onsite administration of 
100 mL of 3 % NaCl over 10 min [236]. Finally, concur-
rent pulmonary edema (putatively neurogenic) should 
not deter physicians to administer 3 % hypertonic saline 
as this treatment can be life-saving in such circumstances 
[238, 239].
If decreased ECFV is the prime mechanism underpin-
ning hyponatremia, then intravenous normal saline ther-
apy is the most judicious choice, besides addressing the 
cause responsible for the contracted EFCV. Of note, nor-
mal saline therapy, routinely deemed as isotonic is in fact 
hypertonic relatively to the plasma osmolarity of hypona-
tremic patients.
Whenever adrenal failure is suspected to be the culprit 
behind the reduced ECVF, administration of 100  mg of 
hydrocortisone should be emergently administrated to 
the patient, after blood sampling for cortisol assessment, 
followed by 100–200  mg of hydrocortisone per 24  h. 
Fludrocortisone is however unnecessary in the acute set-
ting given the mineralocorticoid potency of hydrocorti-
sone when used at high doses [240]. The cornerstone for 
treating patients with suspected CSW is sodium replace-
ment and the restoration of a normal extracellular vol-
ume. 0.9  % NaCl is a reasonable first choice treatment 
but physicians may switch to hypertonic saline therapy 
(either 1.5 or 3 % NaCl) in case PNa levels fail to increase 
[214].
Dodging the risk of OD
Settings at risk for PNa overcorrection
At this point, one reservation should be made about 
the classic differentiation between chronic and acute 
hyponatremia, in terms of risk of OD. Although there is 
undeniable evidence (as exposed previously) that patients 
with chronic hyponatremia face a higher risk of OD, from 
a clinical standpoint this distinction is questionable, as 
the exact onset of hyponatremia is seldom readily avail-
able [241]. One of the better means to prevent OD is to 
limit the occurrence of hyponatremia. In the ICU set-
ting special attention should be paid to ill-motivated 
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prescription of hypotonic fluids, especially in the post-
operative setting.
The next step is to recognize conditions propitious to 
the overcorrection of hyponatremia. A profuse electro-
lyte-free diuresis accompanied with a brisk rise in PNa 
levels is likely to be observed in case of primary polydip-
sia (after implementing water restriction), impaired dilu-
tion (after discontinuation of the culprit drugs, thiazide 
diuretics or anti-psychotic drugs), or after restoration 
of a normal diluting ability once a decreased ECFV has 
been replenished.
When hyponatremic patients are placed on renal 
replacement therapy exceedingly high correction of PNa 
levels may be thwarted by reducing the sodium concen-
tration in the dialysate and shortening the dialysis time.
Setting PNa target levels
The optimal PNa target levels remain an area of con-
troversy. Expert panel recommendations have consist-
ently revised PNa variation to lower thresholds, based 
on accumulating evidence that even small variations of 
PNa levels may expose hyponatremic patients to the 
risk of OD. Originally, 24- and 48-h maximally tolerated 
PNa increases were set at 12 and 25  mmol/L, respec-
tively [78]. Currently, there is a broad consensus that the 
48-h PNa limit should in fact not exceed 15–20 mmol/L. 
As for the 24-h variation limit, goals differ consider-
ably with levels ranging from 4 to 10  mmol/L, accord-
ing to various experts [67, 68, 113]. Advocates of the 
4–6  mmol/L maximum 24-h correction contend that 
a 4  mmol/L rise in PNa levels is sufficient to improve 
the patient’s neurological condition, as previously dis-
cussed, and that OD is arguably unlikely to develop 
when the rise in PNa levels is confined below these lim-
its. The off-side is that keeping PNa levels within such 
narrow margins requires considerable expertise and, at 
any rate, very cautious monitoring. Another challenge 
arises from the fact that maintaining a steady and lim-
ited PNa augmentation should be carried out until PNa 
correction has been fully achieved i.e. the 24- and 48-h 
PNa variation limits should not be misinterpreted as 
requirements restricted to the initial first 24 and 48  h, 
as overcorrection can occur at any time point. Finally, 
a new concept is gradually emerging: rather than rigid, 
universally-applied PNa thresholds, PNa correction 
rates should be tailored individually, depending on each 
patient’s risk factors for OD [67]. Figure 2 summarizes 
the goals of PNa correction.
Dealing with PNa overcorrection
In the event of PNa overcorrection, several studies have 
suggested that halting PNa levels increase and even re-
lowering PNa levels may be protective. In rats subjected 
sequentially to hyponatremia followed by a sudden res-
toration of normal PNa levels, re-inducing a mild level 
of hyponatremia reduced neurological manifestations 
and decreased mortality, as compared to a control 
group of rats deprived of such therapy [242, 243]. In 
the clinical field, anecdotal evidence supports PNa re-
lowering as a means to offset OD; it consists in few case 
reports which have depicted the reversal of OD follow-
ing PNa re-lowering [244, 245]. Nonetheless, given the 
calamitous prognosis of OD most expert recommenda-
tions argue in favor of this strategy [67, 68]. One hin-
drance to PNa re-lowering is that it is usually achieved 
at the expense of the repeated infusion of large volume 
of hypotonic fluids. Not only is it time-consuming for 
caregivers but it may also prove ineffective. An alter-
native resides in the administration of desmopres-
sin, a V2-vasopressin analogue, which promotes water 
reabsorption through V2 receptors activation on the 
collecting duct, thereby reducing urinary water losses 
which serve to increase the PNa. It bears the advantage 
of stopping immediately any further increase of PNa 
levels. PNa levels can thereafter be easily manipulated 
by either administering moderate amounts of hypo-
tonic fluids (i.e. dextrose 5 % in water or even dextrose 
2.5  % in water so as to avoid hyperglycemia) either to 
re-lower PNa to safer levels or to stabilize PNA lev-
els. This technique has proven to be safe and effective 
in terms of PNa kinetics in three independent stud-
ies, and some investigators have even suggested it may 
be used in combination with 3  % NaCl [246–248]. In 
a retrospective study involving 20 patients admitted in 
two ICU for hyponatremia defined as PNa levels infe-
rior to 120  mmol/L and/or neurological symptoms in 
conjunction with an excessive rate of PNa increase, 
the use of DDAVP dramatically reduced the rate of 
PNa correction from a median 0.81  mmol/L/h [inter-
quartile range 0.46, 1.48] to −0.02  mmol/L/h [−0.16, 
1.48] (p  <  0.001) along with a concurrent decrease in 
urine output (650  mL/h [214, 1200] versus 93.5  mL/h 
[43, 143]; p  =  0.003) and a rise in urine osmolarity 
(86  mmol/L [66, 180] versus 209  mmol/L [149;318]; 
p = 0.002). Strikingly, the magnitude of PNa variation 
were also significantly dampened with a maximum var-
iation of 11.5 mmol/L [8.25, 14.5] versus 5 mmol/L [4, 
6.75] (p  <  0.01) before and after DDAVP, respectively 
[246] (see Figs. 3, 4).
There is currently no effective treatment for OD but 
experimental models have provided new insights on its 
physiopathology. More specifically, glucocorticoids (by 
restoring the blood–brain barrier and its anti-inflam-
matory properties) [249] and myo-inositol (by repleting 
brain cells deficiencies in organic osmoles) [250, 251] 
might represent avenues for new therapies in the future.
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Treating hyponatremia in specific settings
Physicians should restrain from an overly aggressive cor-
rection of chronic hyponatremia. The goal is rather to 
obtain a slow, gradual correction of PNa levels since the 
risk for hyponatremic encephalopathy is limited and out-
weighed by the likelihood of OD [229]. In most instances, 
this can be achieved by discontinuing potential offend-
ing drugs (see Table 3) and/or implementing an oral fluid 
restriction protocol.
In case of volume overload, the mainstay of patient 
management is water restriction and loop diuretics. 
Aquaretics (vaptans, see below) require further inves-
tigation before they can be regarded as standard of care 
[252].
The first-line treatment is water restriction in case 
of mild, well-tolerated hyponatremia subsequent to 
SIADH. The response to water restriction is expected 
to be favorable when urine osmolality is relatively low 
(<400  mOsm/H2O/kg), but even in such case a rise in 
PNa levels is delayed until a couple of days after its imple-
mentation. Otherwise, loop diuretics (together with salt 
repletion) and vaptans should be the privileged therapeu-
tic options [174].
Pharmacological therapy of hyponatremia in the ICU: old 
drugs, novel therapies and future perspectives
Various pharmacological strategies have been devised 
to accomplish one common goal which is to reset suffi-
cient levels of urine osmolarity in order to obtain a posi-
tive free water clearance. Drugs achieve this either by 
increasing the osmolar load or restoring tubular diluting 
capacity.
Urea is a small diffusible molecule that is filtered unre-
strictedly by the glomerulus and generates an obligatory 
osmotic diuresis when given at high doses. In the setting 
of SIADH, urea has been proven to be a cost-effective 
means to achieve a gradual improvement of PNa level. 
More recently, investigators have shown similar results 
in critically ill patients, however the underlying mecha-
nism of hyponatremia was predominantly SIADH and 
patients displayed mild to moderate hyponatremia (mean 
PNa  =  124.8  mmol/L) [253, 254]. Due to its delayed 
Fig. 3 Effects of DDAVP on PNa kinetics and urine composition and output in 20 patients admitted in the ICU for severe or profound hyponatremia: 
a PNa correction rate before and after DDAVP administration (n = 20). b Urine osmolarity before and after DDAVP administration (n = 14). c Urine 
output before and after DDAVP administration (n = 11). The box plots indicate median, interquartile ranges (25th and 75th percentiles), and mini‑
mum and maximum values. DDAVP administration allows for a marked reduction in electrolyte‑free water output along with a significant reduction 
in the PNa correction rate. Reproduced with permission of the Clinical Journal of the American Society of Nephrology [246]
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effect on PNa levels, this therapy may not be contem-
plated when managing patients with profound and symp-
tomatic hyponatremia. Furthermore, patient compliance 
to this drug is hampered by its displeasing taste [168].
Demeclocycline, an antibiotic, which belongs to the 
tetracycline family, counteracts the effects of AVP by 
inducing a partial, reversible nephrogenic diabetes 
insipidus [255, 256]. Although studies have ascertained 
its effectiveness in controlling euvolemic hyponatremia 
(SIADH), its use in practice is hampered by its nephro-
toxicity [257].
Vaptans have emerged recently as promising drugs in 
the treatment of euvolemic and hypervolemic hypona-
tremia. They act as competitive antagonists to AVP hin-
dering its binding to its receptors (mainly V2 receptors) 
located on the basolateral pole of the collecting ducts. 
The result is a down regulation of AQP2 and an increase 
of electrolyte-free diuresis [258]. Taken as a whole, stud-
ies focusing on patients with hyponatremia related to 
congestive heart failure [259, 260], cirrhosis [259, 261] 
and SIADH [259] have documented a positive effect of 
the drug on PNa levels but have failed to demonstrate 
that the reversal of mild to moderate hyponatremia 
equates with an improvement in meaningful outcomes. 
Furthermore, hyponatremic patients do not respond uni-
formly to vaptans, cirrhotic patients being less responsive 
to their effects [262]. Numerous impediments hamper 
the use of vaptans in the ICU setting. Their action is not 
immediate and they provide only for a modest increase in 
PNa levels which makes vaptans unsuitable for the treat-
ment of highly symptomatic hyponatremia, unless they 
are used in combination with other strategies [263, 264]. 
To date, only conivaptan may be delivered intravenously 
and its use in the ICU has been confined to case reports 
or small non randomized studies [265]. After a loading 
dose, administration through a continuous intravenous 
perfusion has been advocated. However, this regimen 
comes with a greater risk of vascular irritation and in-
site thrombosis [266]. Other notable side effects include 
hypokalemia, headaches, thirst and drug interactions due 
to competition between vaptans and other CYP3A4 sub-
strates. Finally, although seemingly rare, the risk of PNa 
overcorrection does exist and special attention should 
be paid regarding the occurrence of hyperaquaresis 
upon treatment initiation, especially in cases of chronic 
SIADH.
How vaptans will fit in the therapeutic armamentarium 
of severe symptomatic hyponatremia is thus uncertain. 
Whether vaptans will be utilized as an adjuvant therapy 
to reinforce other measures, or as part of a sequential 
strategy as a relay treatment to hypertonic saline is left 
to speculation [267]. Finally, one must keep in mind that 
vaptans are expensive drugs.
Conclusion
Hyponatremia remains a major bane for the intensivist. 
Not only is it the most frequently encountered electrolyte 
disorder, but it is increasingly recognized as a harbinger 
of dismal outcome in various conditions. The appropriate 
management of hyponatremia requires its timely recog-
nition, a judicious analysis of the underlying mechanisms 
involved in its pathogenesis, and the appreciation of its 
severity and impact on the patient’s course. Above all, 
hyponatremia poses a conundrum which resembles the 
likes of a Zugzwang situation in chess when any move 
worsens the player’s position. In a similar vein, attend-
ing physicians should be reminded that when confronted 
with profound and symptomatic hyponatremia, over-
treating a patient may be as deleterious as failing to ini-
tiate the right therapeutic measures. Fortunately, the 
understanding of the physiopathology of both hypona-
tremic encephalopathy and OD has achieved consider-
able success and may give rise to novel therapies in the 
future.
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